Gut and Liver最新文献

{"title":"Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study.","authors":"Hyun Lim, Ju Yup Lee, Yong Hwan Kwon, Hee Seok Moon, Jong Kyu Park, Ki Bae Kim, Sang Wook Kim, Young Hoon Youn, Sang Gyun Kim, Gwang Ha Kim, Ji Won Kim, Jae-Young Jang, Kye Sook Kwon, Joong Goo Kwon, Hyun-Soo Kim, Su Jin Hong, Kwang Jae Lee, Suck Chei Choi, Jeong Seop Moon, Nayoung Kim, Jong-Jae Park, Yirang Lim, Sung Hee Hong, Hwoon-Yong Jung","doi":"10.5009/gnl240390","DOIUrl":"10.5009/gnl240390","url":null,"abstract":"<p><strong>Background/aims: </strong>Clinical data on the efficacy and safety of the dual delayed-release formulation of 10-mg esomeprazole (HIP2101) are currently limited. Therefore, this study compared the efficacy and safety of HIP2101 and 20-mg famotidine (RLD2101) in patients with gastric erosions.</p><p><strong>Methods: </strong>In this multicenter, randomized, double-blind, active-control, phase III study, 326 patients with endoscopically proven gastric mucosal erosion were randomly assigned to receive either HIP2101 or RLD2101 once daily for 2 weeks. The primary endpoint was the rate of improvement of erosion. Secondary endpoints (rate of cure of erosion and edema, and rate of improvement of hematin and gastrointestinal symptoms) and treatment-emergent adverse events were compared between the groups.</p><p><strong>Results: </strong>Based on the per-protocol set (PPS) analysis, the improvement rates for erosion were 64.9% (98/151) and 63.7% (100/157) in the HIP2101 and RLD2101 groups, respectively (95% confidence interval, -9.5 to 11.9). The lower bound of the 95% confidence interval was greater than the noninferiority margin of -14%. These results were similar to those of the full analysis set (FAS) (HIP2101 group, 64.6%; RLD2101 group, 62.7%). Based on the PPS and FAS analyses, the cure rates for erosion and edema and the improvement rates for hematin and gastrointestinal symptoms were comparable between the groups. The number of adverse events did not differ significantly between the groups.</p><p><strong>Conclusions: </strong>The efficacy and safety of HIP2101 were comparable to those of RLD2101 in the treatment of gastric erosions and symptomatic improvement. These findings suggest that HIP2101 may be a novel treatment option for gastritis (ClinicalTrials.gov identifier: NCT05024721).</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"519-527"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Study on Clinical Features of Autoimmune Gastritis: Impact of Age, Sex, and Autoimmune Thyroid Disease in China.","authors":"Xu Wang, Chun-Jing Lu, Yi Ding, Jin-Yan Zhang, Zhong Xu, Juan Yu, Na Wu, Jian-Hai Wu, Wei-Feng Huang","doi":"10.5009/gnl240448","DOIUrl":"10.5009/gnl240448","url":null,"abstract":"<p><strong>Background/aims: </strong>Autoimmune gastritis (AIG) is an immune-mediated chronic atrophic gastritis. This study aimed to investigate the clinical characteristics of AIG patients, stratified by age, sex, and the presence/absence of autoimmune thyroid disease (AITD).</p><p><strong>Methods: </strong>We reviewed the data of AIG patients treated at a large academic tertiary teaching hospital from January 2018 to October 2023. Patients were grouped according to age (≥60 years or younger), sex, and the presence/absence of AITD and the clinical characteristics of the groups were analyzed.</p><p><strong>Results: </strong>This study included 183 AIG patients. Older patients (≥60 years) had higher rates of pernicious anemia (26.7% vs 11.8%) and intrinsic factor antibodies (36.8% vs 20.9%) than younger patients (<60 years). However, no significant differences were observed in the extent of gastric atrophy, sex ratio, or serum gastrin levels between the age groups. Female patients were more prone than males to exhibit enterochromaffin-like cell hyperplasia (69.4% vs 39.2%) and had a higher prevalence of iron deficiency anemia (IDA) (25.0% vs 0.0%, p=0.004). AIG patients with AITD were younger (50.9±12.0 years vs 58.0±11.5 years), were more likely to be females (p=0.023), and exhibited milder gastric body atrophy (p=0.009) than those without AITD.</p><p><strong>Conclusions: </strong>AIG patients demonstrate age- and sex-related differences in clinical characteristics. Older patients are more likely to have intrinsic factor antibody positivity and pernicious anemia, while women are more prone to IDA. There is a high comorbidity rate between AITD and AIG, and patients with AITD-associated AIG are typically younger and tend to have milder gastric body atrophy.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"528-535"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on Risk Factors for Perforation in Endoscopic Treatment for Early Colorectal Cancer: A Nationwide ENTER-K Study.","authors":"Fayuan Wang, Ping He","doi":"10.5009/gnl250006","DOIUrl":"10.5009/gnl250006","url":null,"abstract":"","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":"19 4","pages":"627-628"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective Study on the Detection of Gastric Neoplasms Using Pepsinogen and Gastrin-17 Levels.","authors":"Sun-Young Lee, Hee-Won Moon, Yeon-Sun Ahn, Joo Hye Song, Jeong Hwan Kim, In-Kyung Sung","doi":"10.5009/gnl240544","DOIUrl":"10.5009/gnl240544","url":null,"abstract":"<p><strong>Background/aims: </strong>GastroPanel tests include gastrin-17 (G-17) levels in addition to pepsinogen (PG) and <i>Helicobacter pylori</i> serology tests. The aim of this study was to identify significant test findings in patients with gastric neoplasms by comparing the findings of GastroPanel tests and conventional serum PG assays.</p><p><strong>Methods: </strong>Consecutive individuals who underwent serological testing were included from May 2023 to August 2024. Foreigners and those with gastrectomy, renal insufficiency, previous <i>H. pylori</i> eradication, and recent acid suppressant use were excluded.</p><p><strong>Results: </strong>Among the 1,101 participants, 122 were diagnosed with gastric neoplasms. High G-17 levels (odds ratio [OR], 1.030; 95% confidence interval [CI], 1.008 to 1.052), low I/II ratios determined by GastroPanel tests (OR, 0.834; 95% CI, 0.779 to 0.894), and low I/II ratios determined by HBI PG assays (OR, 0.584; 95% CI, 0.511 to 0.668) were significant variables for detecting gastric neoplasms. The cutoff values for low I/II ratios were <6.15 (GastroPanel test) and <3.005 (HBI assay), with no differences in diagnostic performance between the two tests (p=0.085). Although the I/II ratio alone was a significant independent variable for detecting early gastric cancers, advanced gastric cancers, adenomas, and neuroendocrine tumors, the G-17 level alone was significant only for adenomas and neuroendocrine tumors. The findings of the patients with gastrointestinal stromal tumors did not differ from those of the controls.</p><p><strong>Conclusions: </strong>Blood test findings are useful for detecting gastric neoplasms, except for gastrointestinal stromal tumors. The addition of G-17 levels to PG tests is only beneficial for diagnosing gastric neoplasms associated with corpus atrophy, such as adenoma and neuroendocrine tumors (ClinicalTrials.gov identifier NCT05883345).</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"548-558"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang","doi":"10.5009/gnl240539","DOIUrl":"10.5009/gnl240539","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as one of the most prevalent chronic liver diseases globally, and its pathogenesis is closely linked to the imbalance of intestinal microbiota and their metabolites. This article reviews the mechanisms through which intestinal microbiota influence the progression of MASLD via the gut-liver axis, elaborating on the complex roles of immune cell hyperactivation, impaired intestinal barrier function, and intestinal microbial metabolites such as short-chain fatty acids and bile acids. The imbalance of intestinal microbiota not only directly promotes the development of MASLD but also further exacerbates disease progression through abnormalities in their metabolites. Various novel therapeutic strategies are being actively developed on the basis of gut-liver axis theory, including probiotic/prebiotic/synbiotic treatment, fecal microbiota transplantation, and targeted drug therapy. These strategies aim to precisely regulate microbial homeostasis and improve glucose and lipid metabolism, thereby alleviating hepatic inflammation and fibrosis and optimizing the therapeutic outcomes of patients with MASLD. In the future, as research progresses, we will further uncover the interaction mechanisms between intestinal microbiota and MASLD and continuously explore more effective treatment methods, with the goal of improving the prognosis and quality of life for MASLD patients.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"479-507"},"PeriodicalIF":3.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer.","authors":"Seokchan Hong, Ji Hyeon Ju, Sang-Heon Lee, Seung-Jae Hong, Sang-Hyon Kim, Ga Young Ahn, Jae Hyun Jung, Jin-Wuk Hur, You-Jung Ha, Jin Kyun Park, Hyun-Sook Kim, Sung Won Lee, Yong-Beom Park, Mie Jin Lim, Yun Sung Kim, Jung Soo Song, Chan-Bum Choi, Seong-Ho Kim, In Ah Choi, Kee Don Choi, Tae Hee Lee, Young Sin Cho, Yong Chan Lee, Kye Sook Kwon, Hyejung Lee, Mihee Park, Junga Heo, Song Baek, Chang-Keun Lee","doi":"10.5009/gnl250019","DOIUrl":"https://doi.org/10.5009/gnl250019","url":null,"abstract":"<p><strong>Background/aims: </strong>To compare the efficacy and safety of fexuprazan and lansoprazole for preventing peptic ulcers (PUs) induced by nonsteroidal anti-inflammatory drugs (NSAIDs).</p><p><strong>Methods: </strong>This multicenter, double-blind, randomized, active-controlled study was conducted across 32 hospitals in South Korea. Patients with musculoskeletal disease requiring long-term treatment with celecoxib, naproxen, or meloxicam were randomized to receive either fexuprazan 20 mg/day (n=212) or lansoprazole 15 mg/day (n=211) for 24 weeks. The primary endpoint was the occurrence of PUs, which were confirmed via esophagogastroduodenoscopy (EGD), with a non-inferiority margin of 8.3%. Only ulcers that developed during the treatment period were examined in the analysis. The occurrence of gastroduodenal bleeding was also monitored via EGD, and symptoms were assessed by using the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM). Adverse events were recorded during the study.</p><p><strong>Results: </strong>The incidence rate of EGD-confirmed PUs at week 24 was 1.16% in the fexuprazan group and 2.76% in the lansoprazole group, with a between-group difference of -1.64% (95% confidence interval, -4.52% to 1.25%), demonstrating non-inferiority. No patients presented with gastroduodenal bleeding. No significant between-group differences were found in the PAGI-SYM scores (leastsquare mean difference in the total score at week 24, -0.42; 95% confidence interval, -2.48 to 1.64; p=0.69). There were low rates of adverse drug reactions in the fexuprazan and lansoprazole groups (8.57% vs 4.78%, respectively p=0.12).</p><p><strong>Conclusions: </strong>Given its non-inferiority to lansoprazole and similar safety profile, fexuprazan is a promising alternative for the prevention of NSAID-induced PUs (ClinicalTrials.gov identifier NCT04784910).</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144495887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of Predictive Models for Gastric Neoplasm Risk Stratification in Screening Esophagogastroduodenoscopy.","authors":"Seokho Myeong, Kyung-Han Song, Donghoon Kang, Yu Kyung Cho, Jae Myung Park","doi":"10.5009/gnl250018","DOIUrl":"https://doi.org/10.5009/gnl250018","url":null,"abstract":"<p><strong>Background/aims: </strong>Stratifying patients for gastric neoplasm risk before screening esophagogastroduodenoscopy (EGD) is challenging. The aim of this study was to develop a prediction model for assessing gastric neoplasm risk in a screening setting.</p><p><strong>Methods: </strong>This retrospective cross-sectional study included 21,586 EGD patients from Seoul St. Mary's Hospital, Korea (2009 to 2019). Logistic regression analyses identified risk factors, and score-based prediction models were developed on the basis of these risk factors. These models were evaluated using the area under the curve (AUC) and the Hosmer‒Lemeshow goodness of fit test. Internal validation was performed using bootstrapping (1,000 resamples) and a validation cohort.</p><p><strong>Results: </strong>The study included 10,414 patients in the derivation cohort and 11,172 in the validation cohort. Gastric dysplasia and cancer were identified in 49 (0.47%) and 35 (0.34%) patients, respectively. Four models were developed, with Model 4 including age, sex, pepsinogen I/II ratio, anti-<i>Helicobacter pylori</i> immunoglobulin G antibody, smoking, body mass index, alcohol use, and family history of gastric cancer. Model 4 had the highest AUC (0.827) in the derivation cohort, while Model 2 achieved the highest AUC (0.788) after risk scores were assigned. Observed prevalence rates were 0.24%, 1.05%, and 4.08% for low-, medium-, and high-risk groups, respectively (p<0.001). In internal validation, Model 3 demonstrated the highest AUC (0.802), with consistent performance in the validation cohort, and all models passed the Hosmer‒Lemeshow test (p>0.8).</p><p><strong>Conclusions: </strong>The predictive models achieved an AUC of approximately 0.8. Further improvements with additional stratification factors are needed for better diagnostic performance in prescreening.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Potassium-Competitive Acid Blocker-Based Triple Therapy with Tegoprazan versus Vonoprazan for <i>Helicobacter pylori</i> Eradication: A Randomized, Double-Blind, Active-Controlled Pilot Study.","authors":"Jae Yong Park, Il Ju Choi, Gwang Ha Kim, Su Jin Hong, Sung Kwan Shin, Seong Woo Jeon, Jae Gyu Kim","doi":"10.5009/gnl250067","DOIUrl":"https://doi.org/10.5009/gnl250067","url":null,"abstract":"<p><strong>Background/aims: </strong>Triple therapy with vonoprazan, a potassium-competitive acid blocker, has shown an acceptable eradication rate. The aim of this study was to evaluate the efficacy and safety of tegoprazan-based triple therapy compared with those of vonoprazan-based triple therapy for <i>Helicobacter pylori</i> eradication.</p><p><strong>Methods: </strong>This randomized, double-blind, active-controlled, multicenter pilot study included treatment-naive adults with <i>H. pylori</i> infection. Participants were randomized 1:1:1 to receive tegoprazan 50 mg (TAC 1), tegoprazan 100 mg (TAC 2), or vonoprazan 20 mg (VAC) with amoxicillin 1,000 mg plus clarithromycin 500 mg twice daily for 10 days. The primary outcome was the eradication rate.</p><p><strong>Results: </strong>Of the 102 enrolled participants, 97 completed the study. The eradication rates in the full analysis set were 60.61% (95% confidence interval [CI], 43.93% to 77.28%), 78.79% (95% CI, 64.84% to 92.74%), and 84.85% (95% CI, 72.62% to 97.08%) in TAC 1, TAC 2, and VAC, respectively. The eradication rates in the per-protocol set were 66.67% (95% CI, 49.80% to 83.54%), 86.67% (95% CI, 74.50% to 98.83%), and 87.50% (95% CI, 76.04% to 98.96%) in TAC 1, TAC 2, and VAC, respectively. In the full analysis set, the eradication rate differences were -6.06% (95% CI, -24.61% to 12.49%) between TAC 2 and VAC and -24.24% (95% CI, -44.92% to -3.56%) between TAC 1 and VAC. In the per-protocol set, the eradication rate differences were -0.83% (95% CI, -19.97% to 17.37%) between TAC 2 and VAC and -20.83% (95% CI, -41.23% to -0.44%) between TAC 1 and VAC. All therapies were well tolerated with no notable safety differences.</p><p><strong>Conclusions: </strong>After 10 days, tegoprazan 100 mg showed eradication rates comparable to those of vonoprazan 20 mg, while 50 mg may be insufficient. These findings support future research to optimize tegoprazan dosing in clinical practice (ClinicalTrials.gov; NCT04128917).</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study.","authors":"Gwang Hyeon Choi, Young-Hoon Chon, Do Hoon Kwon, Sung Nam Jo, Og-Jin Jang, Kyung-Ah Kim, Dahye Baik, Eun Sun Jang, Sook-Hyang Jeong","doi":"10.5009/gnl240451","DOIUrl":"https://doi.org/10.5009/gnl240451","url":null,"abstract":"<p><strong>Background/aims: </strong>Data on hepatitis C virus (HCV) infection among people who use drugs (PWUD) in South Korea is limited. This study investigated the prevalence, clinical characteristics, and treatment rates of HCV infection among PWUD.</p><p><strong>Methods: </strong>From August 2022 to May 2024, 342 PWUD were prospectively enrolled in four hospitals covering 95% of PWUD care in Korea. Blood tests and questionnaires were conducted. If the anti-HCV antibody test was positive, a reflex test for HCV RNA was performed. The clinical characteristics were compared according to anti-HCV or HCV RNA positivity.</p><p><strong>Results: </strong>Among these patients (median age, 46 years; men, 76%; injection drug user, 92%; syringe sharing, 56%), the prevalence of anti-HCV and HCV RNA was 31.3% and 10.5%, respectively. Abnormal aspartate aminotransferase or alanine aminotransferase levels were found in 24.6% of patients, and fibrosis-4 >3.25 was detected in 4.4% of patients. Anti-HCV positivity was independently associated with age (odds ratio [OR], 1.074), duration of injection drug use (OR, 1.060), sharing of syringes (OR, 3.510), and very low monthly income (OR, 2.598). Among anti-HCV positive patients, the treatment rate was significantly higher in the HCV RNA negative group (71.8%) than in the RNA positive group (16.7%). The only independent factor related to treatment uptake was having Medical Aid, which reimbursed 100% of the antiviral treatment (OR, 10.912; 95% confidence interval, 2.024 to 58.848; p=0.005).</p><p><strong>Conclusions: </strong>Among PWUD in South Korea, the anti-HCV and HCV RNA prevalence rates were 31.3% and 10.5%, respectively. Only half of the anti-HCV positive PWUD received antiviral treatment. Treatment uptake was related to direct-acting antiviral affordability, suggesting a need for public support.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Serum Pepsinogen Tests in Detection of Gastric Atrophy, Intestinal Metaplasia, Gastric Adenoma, and Gastric Cancer in South Korea.","authors":"Yonghoon Choi, Nayoung Kim, Ji Hyun Park, Jeong Hwan Lee, Yeejin Kim, Ho-Kyoung Lee, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee","doi":"10.5009/gnl250055","DOIUrl":"https://doi.org/10.5009/gnl250055","url":null,"abstract":"<p><strong>Background/aims: </strong>The aim of this study was to evaluate the efficacy of serum pepsinogen (sPG) tests for gastritis, gastric adenoma (GA), and gastric cancer (GC) using the enzyme‑linked immunosorbent assay-based GastroPanel kit and to investigate the correlation between Gastro-Panel- and Latex-enhanced Turbidimetric Immunoassay (L-TIA)-derived sPG results.</p><p><strong>Methods: </strong>sPG I and II levels and PG I/II ratios were measured using both kits in 2,204 participants, including 1,109 controls, 316 GA, and 779 GC patients.</p><p><strong>Results: </strong>The GastroPanel- and L-TIA-derived sPG results showed high concordance. An sPG I concentration of 70 ng/mL and a PG I/II ratio of 3 measured with the L-TIA kit corresponded to 100 ng/mL and 5.3 with the GastroPanel kit. sPG I decreased in the GA and GC groups, whereas sPG II was lower in the GA group, but higher in the GC group than that in control group. The PG I/II ratios significantly decreased in the GA and GC groups, especially for the intestinal type. The sensitivity and specificity of PG I/II ratio ≤5.3 using the GastroPanel kit for the detection of GA or GC were 51%-59% and 61%-66%, respectively, which were slightly higher than 51%-58% and 58%-63% using the L-TIA kit. The group with a PG I/II ratio ≤5.3 and <i>Helicobacter pylori</i>-negative status had the highest risk with an adjusted odds ratio of 3.36 for GA and 2.25 for GC, with more prominent increase in diffuse-type compared to intestinal-type.</p><p><strong>Conclusions: </strong>The GastroPanel kit showed non-inferiority compared to the L-TIA kit.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}